Education
About Us
Working with TipRanks
Follow Us
BioLineRX Ltd. (IL:BLRX)
:BLRX
BLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range1.40 - 20.80
Previous CloseN/A
Volume20.50M
Average Volume (3M)14.57M
Market Cap
69.06M
Enterprise Value36.27M
Total Cash (Recent Filing)19.56M
Total Debt (Recent Filing)$15.04M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 13, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,557,611,000
10 Day Avg. Volume26,571,261
30 Day Avg. Volume14,574,513
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.30
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit1.84
Enterprise Value/Ebitda-0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.40 and its highest was 20.80 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is 69.06M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is Aug 13, 2025 which is in 53 days.
How were BioLineRX Ltd.’s earnings last quarter?
Currently, no data Available
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is -0.35.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,557,611,000 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.